Clin Exp Vaccine Res.  2023 Apr;12(2):172-175. 10.7774/cevr.2023.12.2.172.

A case report overlapped vaccine and COVID-19 in disseminated atherosclerosis

• Bayrak V

• KMID: 2552357
• DOI: http://doi.org/10.7774/cevr.2023.12.2.172

Abstract

Coronavirus disease 2019 (COVID-19) has become a part of our lives now and we have no more effective way of coping than a vaccine. COVID-19 is a disease that causes severe thrombosis outside the respiratory tract. Vaccines also protect us in this respect, but in some rare cases, thrombosis has been found to develop after vaccination (much less frequently than COVID-19). What was interesting in our case was that it showed how a disaster could happen under three factors that predispose to thrombosis. A 65-year-old female patient with disseminated atherosclerosis was admitted to the intensive care unit with complaints of dyspnea and dysphasia. In the evening of the day, the patient had the vaccination 2 weeks ago, she had active COVID-19. On examination, lower extremity pulses could not be detected. The patient’s imaging and blood tests were performed. Multiple complications such as embolic stroke, venous and arterial thrombosis, pulmonary embolism, and pericarditis were observed in the patient. This case may give consideration to anticoagulant therapy studies. We give effective anticoagulant therapy in the presence of COVID-19 in patients at risk of thrombosis. Can anticoagulant therapy be considered after vaccination in patients at risk of thrombosis such as disseminated atherosclerosis?

Keyword

Messenger RNA; Vaccination; Middle cerebral artery thrombosis; Anticoagulant agent; Heterologous effects of vaccines; Case report